Last reviewed · How we verify
rivaroxaban (10mg)
Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation.
Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.
At a glance
| Generic name | rivaroxaban (10mg) |
|---|---|
| Also known as | Xarelto, Rivaroxaban |
| Sponsor | Chang Gung Memorial Hospital |
| Drug class | Direct Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban selectively inhibits Factor Xa, a serine protease essential for both the intrinsic and extrinsic pathways of the coagulation cascade. By blocking Factor Xa, the drug prevents the conversion of prothrombin to thrombin, thereby reducing thrombin-mediated fibrin clot formation. This anticoagulant effect is used to prevent and treat thrombotic events.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) treatment and prevention
- Pulmonary embolism (PE) treatment and prevention
- Acute coronary syndrome (ACS) in combination with antiplatelet therapy
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
- Abdominal pain
Key clinical trials
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention (PHASE4)
- A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg (PHASE2, PHASE3)
- Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma (PHASE3)
- Excretion of Rivaroxaban in Human Breast Milk (PHASE1)
- Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters (PHASE3)
- Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery (NA)
- THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rivaroxaban (10mg) CI brief — competitive landscape report
- rivaroxaban (10mg) updates RSS · CI watch RSS
- Chang Gung Memorial Hospital portfolio CI